MEDICAL RESEARCH NETWORK LTD
MEDICAL RESEARCH NETWORK
- 2022 International Trade
Medical Research Network (MRN) is the highly innovative, market-leading, clinical trial support organisation and power behind the revolution of decentralised clinical trials for over 16 years. MRN conducts clinical trials in patients’ homes through the deployment of healthcare professionals (Clinical solutions) and employment of study appropriate digital technology (eClinical solutions). Its Home Trial Support service allows patients to participate in trials when and where they want.
Enhancing the delivery of clinical trials
Running trials in a patient’s community has proven to increase recruitment rates and improve retention rates of patients in clinical trials, two well-known, and serious, challenges in clinical research. The result: medicines can get to the market, and so treat patients, much sooner.
While many clinical trials can benefit from the use of Home Trial Support, MRN has grown by working on ‘difficult’ trials: those with large numbers of countries, where drugs must be infused or injected by a nurse and/or those with challenging paediatric or rare-disease patient populations – often difficult to recruit into studies due to geographical location. MRN’s unparalleled innovative and creative in-home visit design, combining clinical and digital decentralised elements, enhances the delivery of clinical trials, making them more flexible, with improved data quality and more efficient.
A great honour
Graham Wylie, Founder and CEO, commented: “We are honored to receive the prestigious Queen’s Award as it recognises the incredible growth of our business and the dedication of our employees, global network of healthcare professionals, vendors, and partners. We are dedicated to making healthcare more accessible for patients, clinical trials less burdensome for families and helping bring new medicines to people faster.
”Decentralised clinical trials were instrumental in rescuing many clinical trials through the Covid-19 pandemic. MRN, already one of the UK’s fastest growing healthcare businesses, saw the impact of the pandemic on global clinical research firsthand. As the pandemic hit, the clinical trial industry urgently needed to pivot many trials into the decentralized model, away from hospitals/research centers – MRN stepped up and delivered.
Despite all the issues Covid-19 still causes, MRN continues to deliver for the expanding customer base. This is due to MRN’s systems, processes and, most of all, the dedication and hard work of its passionate employees and allies who believe in the decentralised trial model as the future of clinical research.
Stuart Redding (COO), added: “We will continue to drive the decentralised clinical trial market by continuing to innovate, expand our geographical reach, enhance our solutions with digital technology and expanding our portfolio of services organically and through an active acquisition policy. We do this to deliver clinical trials to patients in their own communities around the globe efficiently. This award is a further validation of our position as the catalysts of decentralised clinical trials, designing and scaling trials quickly and efficiently, bringing medicines to market faster.”